Patents by Inventor Brian Kent Rhees
Brian Kent Rhees has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150828Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fotal and matemal cfDNA by massively parallel sequencing. The method comprises a novel protocol for prepering sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: ApplicationFiled: December 11, 2023Publication date: May 9, 2024Applicant: Verinata Health, Inc.Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Patent number: 11884975Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: GrantFiled: March 5, 2021Date of Patent: January 30, 2024Assignee: VERINATA HEALTH, INC.Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Publication number: 20220228197Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions. CNV that can be determined according to the present method include trisomies and monosomies of any one or more of chromosomes 1-22, X and Y, other chromosomal polysomies, and deletions and/or duplications of segments of any one or more of the chromosomes, which can be detected by sequencing only once the nucleic acids of a test sample.Type: ApplicationFiled: April 8, 2022Publication date: July 21, 2022Applicant: Verinata Health, Inc.Inventors: Richard P. Rava, David A. Comstock, Brian Kent Rhees
-
Patent number: 11332774Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions. CNV that can be determined according to the present method include trisomies and monosomies of any one or more of chromosomes 1-22, X and Y, other chromosomal polysomies, and deletions and/or duplications of segments of any one or more of the chromosomes, which can be detected by sequencing only once the nucleic acids of a test sample.Type: GrantFiled: July 25, 2017Date of Patent: May 17, 2022Assignee: Verinata Health, Inc.Inventors: Richard P Rava, David A Comstock, Brian Kent Rhees
-
Publication number: 20220106639Abstract: The invention includes a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions.Type: ApplicationFiled: December 17, 2021Publication date: April 7, 2022Inventors: Richard P. Rava, Brian Kent Rhees
-
Patent number: 11286520Abstract: A method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions.Type: GrantFiled: July 31, 2017Date of Patent: March 29, 2022Assignee: Verinata Health, Inc.Inventors: Richard P Rava, Brian Kent Rhees
-
Publication number: 20210340613Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: ApplicationFiled: March 5, 2021Publication date: November 4, 2021Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Patent number: 10941442Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: GrantFiled: May 22, 2017Date of Patent: March 9, 2021Assignee: Verinata Health, Inc.Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Publication number: 20180016625Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions. CNV that can be determined according to the present method include trisomies and monosomies of any one or more of chromosomes 1-22, X and Y, other chromosomal polysomies, and deletions and/or duplications of segments of any one or more of the chromosomes, which can be detected by sequencing only once the nucleic acids of a test sample.Type: ApplicationFiled: July 25, 2017Publication date: January 18, 2018Inventors: Richard P Rava, David A Comstock, Brian Kent Rhees
-
Publication number: 20170327881Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: ApplicationFiled: May 22, 2017Publication date: November 16, 2017Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Publication number: 20170327884Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions.Type: ApplicationFiled: July 31, 2017Publication date: November 16, 2017Inventors: Richard P. Rava, Brian Kent Rhees
-
Patent number: 9657342Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: GrantFiled: December 1, 2010Date of Patent: May 23, 2017Assignee: Verinata Health, Inc.Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Publication number: 20120270739Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses. The novel protocol can be performed in solution or on a solid surface.Type: ApplicationFiled: May 29, 2012Publication date: October 25, 2012Applicant: VERINATA HEALTH, INC.Inventors: RICHARD P. RAVA, DAVID A. COMSTOCK, BRIAN KENT RHEES, ANUPAMA SRINIVASAN
-
Publication number: 20120094849Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Verinata Health, Inc.Inventors: Richard P. Rava, Brian Kent Rhees
-
Publication number: 20110245085Abstract: The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions.Type: ApplicationFiled: December 1, 2010Publication date: October 6, 2011Inventors: Richard P. Rava, Brian Kent Rhees
-
Publication number: 20110201507Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.Type: ApplicationFiled: December 1, 2010Publication date: August 18, 2011Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
-
Publication number: 20090130660Abstract: Association of Type 2 diabetes with single nucleotide polymorphisms and haplotypes are disclosed. Also disclosed are diagnostic applications in identifying those who have Type 2 diabetes or are at risk of developing Type 2 diabetes, and discovery of therapeutic agents and methods of treatment.Type: ApplicationFiled: December 5, 2005Publication date: May 21, 2009Inventors: Malek Faham, Soren Germer, Hywel Bowden Jones, Delphine Lagarde, Mitchell Lee Martin, Martin Emilio Moorhead, Erik Roy Rasmussen, Brian Kent Rhees, James Andrew Rosinski